Ameloblastic fibroma (AF) is a benign tumor of odontogenic origin. It is composed of proliferative odontogenic epithelium and mesenchymal tissue resembling primitive dental papilla. Comprising approximately 2.5% of odontogenic tumors, AF was first described by Kruse et al1 in 1891. It is more common in children than adults; the average age of onset is 15 years (range, 7 weeks to 42 years).1- 3 There is no apparent predilection for race or sex.2,4 The most common clinical presentation is painless facial swelling, although delayed tooth eruption and gingival cysts have been reported as well.4- 6 Radiographically, the lesion appears as unilocular or multilocular radiolucencies. Expansion of the cortex is occasionally seen, and involvement with unerupted teeth is common. The lesions are primarily intraosseous ranging in size from 0.5 to 8.5 cm with 80% to 90% of lesions occurring in the mandible.1,4 The clinical differential diagnosis, which requires histopathologic studies, includes neuroectodermal tumor of infancy, ameloblastoma, odontogenic or developmental cyst, ameloblastic fibrosarcoma, and osteogenic sarcoma.